Compare ImmunityBio Inc. Common Stock (IBRX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Royal Bank of Canada — how do they compare? ImmunityBio Inc. Common Stock trades at $10.03 (market cap $10.51B), while Royal Bank of Canada trades at $191.77 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 25× ImmunityBio Inc. Common Stock's market cap, and Royal Bank of Canada pays a 2.66% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Royal Bank of Canada for 47 Days on average.
| IBRX | RY | |
|---|---|---|
Market Cap | $10.51B | $262.99B |
Volume | 10,445,785 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $11.55 | $217.87 |
52-Week Low | $1.98 | $143.64 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $10.97B | $730.11B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royal Bank of Canada (RY) trades at $191.22, down 2.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 versus $2.89 expected, and robust profitability with a 32.01% net income margin. Revenue growth accelerated to $66.53B in 2025, and the company maintains a solid dividend, with recent payouts of $1.76 per share. Analyst sentiment is mixed, with a Buy consensus of 43% but technical indicators pointing to near-term pressure.
RY presents a value opportunity with a reasonable P/E of 17.2 and strong ROE of 17.2%, supported by earnings momentum and strategic initiatives like global transaction banking integration. Risks include stretched valuations relative to peers, a high EV/EBITDA of 23.52, and macroeconomic sensitivity. The stock's current price near support at $189 suggests potential stability, but investors should weigh fundamental strength against technical bearishness and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
